AC
AVNR

Ascend Capital’s AVANIR PHARMACEUTICALS, INC CL A AVNR Stock Holding History

Ascend Capital’s Portfolio AVNR Stock Details AVNR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-75,000
Closed -$252K – 259
2013
Q4 		$252K Sell
75,000
-904,370
-92% -$3.74M 0.01% 178
2013
Q3 		$4.14M Buy
+979,370
New +$4.64M 0.15% 146

Other funds holding AVNR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Ascend Capital's AVNR Position: Q1 2014 in Review

Ascend Capital sold out of AVANIR PHARMACEUTICALS, INC CL A (AVNR) in Q1 2014, closing a stake of 75,000 shares — an estimated $252K sold.

Ascend Capital first reported a position in AVNR in Q3 2013 and held it in 2 quarters. The position peaked at $4.14M in Q3 2013. 100 funds tracked by Wall St. Rank hold AVNR as of Q1 2014.

  • Ascend Capital reported no remaining AVANIR PHARMACEUTICALS, INC CL A position as of Q1 2014 after selling out during the quarter.
  • Ascend Capital sold 75,000 AVANIR PHARMACEUTICALS, INC CL A shares in Q1 2014, an estimated $252K.
  • Ascend Capital first reported a position in AVANIR PHARMACEUTICALS, INC CL A in Q3 2013 and held it in 2 quarters.
  • Ascend Capital's AVANIR PHARMACEUTICALS, INC CL A position peaked at $4.14M in Q3 2013.
  • 100 funds tracked by Wall St. Rank held AVANIR PHARMACEUTICALS, INC CL A as of Q1 2014.

Based on Ascend Capital's 13F filing for Q1 2014, filed 14 May 2014.